562 related articles for article (PubMed ID: 25996974)
1. 18F-FDG PET/CT is useful in initial staging, restaging for pediatric rhabdomyosarcoma.
Dong Y; Zhang X; Wang S; Chen S; Ma C
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):438-446. PubMed ID: 25996974
[TBL] [Abstract][Full Text] [Related]
2. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma.
Ricard F; Cimarelli S; Deshayes E; Mognetti T; Thiesse P; Giammarile F
Clin Nucl Med; 2011 Aug; 36(8):672-7. PubMed ID: 21716019
[TBL] [Abstract][Full Text] [Related]
3. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas.
Eugene T; Corradini N; Carlier T; Dupas B; Leux C; Bodet-Milin C
Nucl Med Commun; 2012 Oct; 33(10):1089-95. PubMed ID: 22929116
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
7. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
8. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
[TBL] [Abstract][Full Text] [Related]
9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
10. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of
Hotta M; Minamimoto R; Yano H; Gohda Y; Shuno Y
Cancer Imaging; 2018 Jan; 18(1):4. PubMed ID: 29378659
[TBL] [Abstract][Full Text] [Related]
12. Role of
Mercolini F; Zucchetta P; Jehanno N; Corradini N; Van Rijn RR; Rogers T; Cameron A; Scarzello G; Coppadoro B; Minard-Colin V; Gallego S; Chisholm J; Merks JH; Bisogno G
Eur J Cancer; 2021 Sep; 155():155-162. PubMed ID: 34385068
[TBL] [Abstract][Full Text] [Related]
13. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
14. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
Zhang C; Liang Z; Liu W; Zeng X; Mo Y
BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
16. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
18. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
19. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
20. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]